Kolitz, J E <br/><br/>
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.  [electronic resource] 

 -  Journal of biological response modifiers  Oct 1988 
 - 457-72 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-6580 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal<br/>Antigens, Surface--analysis<br/>Cyclophosphamide--administration & dosage<br/>Cytotoxicity, Immunologic--drug effects<br/>Drug Evaluation<br/>Drug Therapy, Combination<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Immunity, Cellular--drug effects<br/>Injections, Subcutaneous<br/>Interleukin-2--administration & dosage<br/>Male<br/>Middle Aged<br/>Mitogens<br/>Neoplasms--therapy<br/>Random Allocation<br/>Recombinant Proteins--administration & dosage<br/>T-Lymphocytes--drug effects<br/>Time Factors